NDAINTRAVENOUSSOLUTION
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Clinical Trials (1)
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
Started Mar 2026
Loss of Exclusivity
LOE Date
Nov 27, 2041
191 months away
Patent Expiry
Nov 27, 2041
Exclusivity Expiry
May 25, 2028